368 related articles for article (PubMed ID: 25870325)
1. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
Santos JR; Saumoy M; Curran A; Bravo I; Llibre JM; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R;
Clin Infect Dis; 2015 Aug; 61(3):403-8. PubMed ID: 25870325
[TBL] [Abstract][Full Text] [Related]
2. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.
Santos JR; Saumoy M; Curran A; Bravo I; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19550. PubMed ID: 25394057
[TBL] [Abstract][Full Text] [Related]
3. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
5. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
[TBL] [Abstract][Full Text] [Related]
7. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
8. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
[TBL] [Abstract][Full Text] [Related]
9. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
11. Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs . 3TC+EFV+TDF.
Wang X; Liu A; Li Z; Zhang H; Wu RE; Shao Y; Li J; Ye J; Liu W; Sun L
Chin Med J (Engl); 2024 Jun; 137(12):1447-1452. PubMed ID: 38816366
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
Clin Infect Dis; 2018 Jul; 67(3):411-419. PubMed ID: 29415175
[TBL] [Abstract][Full Text] [Related]
13. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
14. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
16. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
17. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
Arae H; Tateyama M; Nakamura H; Tasato D; Kami K; Miyagi K; Maeda S; Uehara H; Moromi M; Nakamura K; Fujita J
Intern Med; 2016; 55(23):3435-3440. PubMed ID: 27904105
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
20. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]